✦ LIBER ✦

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

✍ Scribed by Zhu, A. X.; Finn, R. S.; Mulcahy, M.; Gurtler, J.; Sun, W.; Schwartz, J. D.; Dalal, R. P.; Joshi, A.; Hozak, R. R.; Xu, Y.; Ancukiewicz, M.; Jain, R. K.; Nugent, F. W.; Duda, D. G.; Stuart, K.

Book ID: 121360713
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 517 KB
Volume: 19
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-13-1442

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of mapatumumab, a fully hu

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

✍ Greco, F. Anthony; Bonomi, Philip; Crawford, Jeffrey; Kelly, Karen; Oh, Yun; Hal 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 214 KB

364 The first-in-human, first-in-class s

364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer

✍ T. Shimizu; A.W. Tolcher; P. LoRusso; K. Papadopoulos; A. Patnaik; L. Smith; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

415 A phase I study evaluating the safet

415 A phase I study evaluating the safety profile and pharmacokinetics of CS-1008 (Tigatuzumab), humanized monoclonal antibody targeting death receptor 5 (DR5), in Japanese patients with advanced solid tumours

✍ H. Nokihara; N. Yamamoto; Y. Yamada; H. Asahina; T. Shibata; Y. Seki; Y. Tamura; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

197 A phase I and pharmacokinetic (PK) s

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

✍ J. de Bono; G. Attard; R. Plummer; S. Pacey; C. Bale; L. Vidal; A. Greystoke; N. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 138 KB

6579 Cetuximab with Irinotecan/Folinic A

6579 Cetuximab with Irinotecan/Folinic Acid/5-FU as first-line treatment in advanced gastric cancer: a prospective multi-center phase II study and additional biomarkers of the Arbeitsgemeinschaft Internistische Onkologie

✍ Möhler, M.; Mueller, A.; Trarbach, T.; Seufferlein, T.; Kubicka, S.; Lordick, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Docetaxel and carboplatin as first-line

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group

✍ J Pfisterer; A du Bois; U Wagner; J Quaas; J.U Blohmer; D Wallwiener; F Hilpert 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 123 KB